Covid-19 Vaccine: UK Experts Caution Against Hopes Of ‘Return To Normal’
Distribution of Pfizer/BioNTech Vaccine Will Be A ‘Mammoth’ Logistical Operation
Executive Summary
The Pfizer/BioNTech coronavirus vaccine results are a cause for celebration, but there is still a long way to go. Safety data are still awaited, as is more information on efficacy, and the mass rollout of the vaccine will pose significant practical challenges.
You may also be interested in...
Coronavirus Notebook: Pfizer/BioNTech & Russian Vaccines Each Claim Efficacy Of More than 90%
As data start to come in on the first coronavirus vaccines, hopes are rising that vaccination campaigns will be able to begin in the next month or two, although experts have cautioned against unbridled optimism. Uncertainties also remain over questions such as whom to vaccinate first and how to assure equitable access in less wealthy parts of the world.
The World Celebrates Pfizer's 90% COVID-19 Vaccine Efficacy Data, With Cautious Caveats
Pfizer's vaccine for COVID-19 outpaced expectations on efficacy, driving a stock market rally and garnering reaction from Vice President Pence and President-elect Biden.
Brexit: UK Secures Ferry Space For Medicines To Circumvent Port Delays
New checks due to be imposed when the UK leaves the EU single market and customs union in 2021 are expected to cause widespread disruption to consignments of medicines and other vital goods at the Channel ports. The government says it has secured space on nine new ferry routes in an effort to help keep supplies going.